ArticleHaematologica2023

Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia.

Patrick Harrington et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.